This article is the original translational medicine network, please indicate the source for reprinting
Author: Tiffany
Introduction: Targeted cell therapy is a biological immunotherapy method, it is currently the most advanced and promising organism Cell diagnosis and treatment technology can kill viruses directly or indirectly, and can stimulate one's own immune function, strengthen the immune system, and organize tumor growth and metastasis. It has become the fourth largest hepatitis B small three positive treatment mode after surgery, radiotherapy and chemotherapy. Due to its 's advantages such as safety, effectiveness, and low toxic and side effects , this technology has been considered as the most active and promising method of in the comprehensive treatment model of hepatitis B and small three positives. Recently, Legend Biotech is advancing the cell therapy platform for hematological malignancies, solid tumors, infectious and autoimmune diseases...
In 2020, at the American Society of Hematology meeting, people I am looking forward to the latest results of the Phase 1b/2 CARTITUDE-1 clinical trial! The trial evaluated the B cell mature antigen targeted chimeric antigen receptor (CAR) T cell therapy currently under study, formerly known as ciltacabtagene autoleucel (abbreviation: cilta-cel) , which was developed by Legend Biotech and Jointly developed by Janssen Biotech. They published the results of this research in an article titled "Advancing targeted cell therapies to meet unmet needs in oncology and beyond" in "Nature" magazine:
The results of their research are very exciting .The trial studied 97 patients with relapsed or refractory multiple myeloma . These patients have received an average of 6 treatments before . The results of the trial show that: a single low-dose cilta-cel infusion can lead to an early, deep and long-lasting response, and its overall remission rate for patients’ symptoms is 97% ; among them, 67% of patients have been in the past 12 and a half months The remission within time has almost reached a very complete Chengdu, and the survival rate of patients who have not progressed within 12 months has also reached 77%. These scientists also found in their experiments: The safety efficacy of is controllable under the recommended phase 2 dose .
Legend Biotech’s CEO and CFO Dr. Ying Huang (transliteration) said: “These strong results in our experiment can well illustrate: cilta-cel is an effective treatment. It has many advantages, such as: It has high safety performance and is very easy for us to control and manage. For those who have been treated before, but are not effective for the current three mature multiple myeloma-a proteasome inhibitor treatments Patients, this method of immunomodulatory drugs and anti-CD38 antibodies can have an effective therapeutic effect on them.
Based on these results, Janssen Biotech began to submit a cilta- to the U.S. Food and Drug Administration at the end of 2020. The cel biologics license application has also advanced plans to submit license applications to the market in Europe, China, Japan and other places. In addition, a comprehensive clinical research and development project has been launched on cilta-cel in multiple myeloma_ Span8span’s application in early treatment.
Targeted B cell maturation to treat multiple myeloma
Multiple myeloma is the third most common type of blood cancer.It accounts for 13% of all hematological malignancies. Although new drugs and treatments for this disease are in a rapid development stage in recent years, the patient’s condition still has not been effectively cured, and it will continue to relapse after a period of time, and the existing treatments are effective against it. Ineffective, resulting in a very worrying quality of life and prognosis for patients.
In recent years, CAR-T therapy has become a promising option in the treatment of blood cancer. In CAR-T therapy, the patient's T cell is modified to make it easier to identify and target specific proteins on cancer cells. Since B cell maturation resistance is highly expressed on myeloma cells, it has been designated as a strong target for CAR-T therapy . Cilta-cel is a structurally differentiated CAR-T with two B cell maturation anti-targeting domains.
In China, scientists from multiple research institutes have carried out a study in humans for the first time. This experiment is aimed at a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma. It shows a high degree of The response rate and controllable safety. Dr. Ying Huang explained: "The response observed in these patients with the treatment method is significant, and their condition has improved." Legend Biotech was jointly held by the American Society of Clinical Oncology and the American Society of Hematology in 2017. The conference showed the results of their early trials, and subsequently, they reached a global cooperation and licensing agreement with Janssen Biotech, the world's leading pharmaceutical product research and development company. In just 3 years, this cooperation has rapidly developed from the signing of an agreement to the stage of submitting a license application for cilta-cel.
promotes an advanced channel of R&D
Legend Biotech relies on ’s advanced R&D capabilities and an experienced global leadership team ,They are creating and reforming their product channels for the development of autologous and allogeneic therapies for different indications (including hematological malignancies, solid tumors, infectious diseases and autoimmune diseases ).
This picture shows the powerful product channels of next-generation cell therapy developed by Legend Biotech. This channel includes autologous and allogeneic treatments targeting hematological malignancies, solid tumors, infectious diseases and autoimmune diseases. Acute myeloid leukemia, B-cell maturation antigen, diffuse large B-cell lymphoma, follicular lymphoma, HIV (human immunodeficiency virus), mantle cell lymphoma, non-Hodgkin lymphoma , Multiple myeloma, mesothelin, small lymphocytic lymphoma, T cell lymphoma, etc.
Recently, the US Food and Drug Administration approved an experimental new drug LB1901 (autologous CAR-T therapy for the treatment of relapsed and refractory T-cell lymphoma in adults), which will promote Legend Biotech's technology in The United States has launched a new phase of research. LB1901 targets CD4, a surface membrane glycoprotein that is expressed in most TCL subtypes.
Legend Biotech is also developing allogeneic CAR-T therapy targeting CD20 and BCMA and autologous CAR-T therapy targeting Claudin 18.2, which will be suitable for advanced pancreatic cancer and gastric cancer.
Dr. Ying Huang concluded: " cell therapy brings a lot of hope for various difficult-to-treat cancers. We will continue to explore the full potential of CAR-T cell therapy, and strive to provide doctors and patients with innovations. The treatment method ."
Reference:
https://www.nature.com/articles/d43747-021-00021-1?mvt=i&mvn=5ec110142d9c41ecb1fb888e28b19c95&mvp=NA-mvCOM-11239458&mvp=NA-Homepage% 20150%20%5BHome%20Layout%20-%20New%20Design%5D
Note: This article aims to introduce the progress of medical research,Can not be used as a reference for treatment options. If you need health guidance, please go to a regular hospital.
Popular·Article
diagnostic test
[The Lancet] Call for action! Nearly half of the world's people cannot get basic diagnosis for many common diseases. Can the COVID-19 pandemic help change the diagnosis?
immunotherapy
[Nature Sub-Journal] Does lung epithelial cells control lung immunity? This will lay the foundation for the treatment of many lung diseases!
Tumor Research
[Research] Be alert! Summarizing 30 years of big data: esophageal adenocarcinoma is showing a younger trend
Medical News
[News] The 2021 Nobel Prize in Physiology or Medicine will be announced, and pain receptors won!
Intestinal health
【PNAS】Research has discovered the "second brain" that exists in the intestine, and its glial will open up new ways to treat intestinal diseases!
Tumor research
[Nature sub-Journal] New ideas for studying tumor cells using single-cell multi-omics,Top-level teams such as Harvard Medical School create a precedent!
Tumor research
【Science】Protein may become a new breakthrough in cancer treatment!
new coronavirus
[Science] The truth about the source of SARS-CoV-2 is revealed? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.8%!
Covid-19
【The BMJ】Israel, with a vaccination rate of 78%, why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection?
Organoid Research
[Nature] A 3D pancreatic cancer tumor model developed by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer
Tumor Research
[Science Sub-Journal] Table salt has the effect of inhibiting tumors? Scientists explain unexpected discoveries for you through mouse experiments!
Recommendations and Activities
The 3rd Shanghai International Cancer Conference
The 5th Modern Clinical Molecular Diagnosis Symposium
.
